PositiveID Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
945.00
2,940.00
5,559.00
5,359.00
Cost of Goods Sold (COGS) incl. D&A
372.00
294.00
335.00
3,537.00
3,514.00
Gross Income
372.00
651.00
2,605.00
2,022.00
1,845.00
SG&A Expense
4,582.00
4,901.00
7,031.00
9,169.00
6,348.00
EBIT
4,954.00
4,250.00
4,426.00
7,147.00
4,503.00
Unusual Expense
8.00
70.00
2,660.00
1,676.00
566.00
Non Operating Income/Expense
1,511.00
1.00
401.00
62.00
49.00
Interest Expense
507.00
3,010.00
4,719.00
7,652.00
3,713.00
Pretax Income
3,958.00
7,191.00
11,404.00
13,061.00
8,733.00
Income Tax
371.00
-
-
-
-
Consolidated Net Income
13,294.00
7,191.00
11,404.00
13,061.00
8,733.00
Net Income
13,294.00
7,191.00
11,404.00
13,061.00
8,567.00
Net Income After Extraordinaries
13,294.00
7,191.00
11,404.00
13,061.00
8,567.00
Net Income Available to Common
13,336.00
8,223.00
11,510.00
13,216.00
8,748.00
EPS (Basic)
106,446,776.61
13,493,253.37
5,997,001.50
180,180.18
150.00
Basic Shares Outstanding
0.00
0.00
0.00
0.10
57.80
EPS (Diluted)
106,657,436.25
12,761,988.19
5,634,825.65
167,694.09
151.28
Diluted Shares Outstanding
0.00
0.00
0.00
0.10
57.80
EBITDA
4,582.00
3,962.00
4,168.00
6,847.00
4,300.00
Minority Interest Expense
-
-
-
-
166.00
Other After Tax Income (Expense)
8,965.00
-
-
-
-
Preferred Dividends
42.00
1,032.00
106.00
155.00
181.00

About PositiveID

View Profile
Address
1690 South Congress Avenue
Delray Beach Florida 33445
United States
Employees -
Website http://www.psidcorp.com
Updated 07/08/2019
PositiveID Corp. engages in the development of molecular diagnostic systems for bio-threat detection and rapid medical testing. It operates through the following segments: Molecular Diagnostics, Medical Devices, Mobile Labs, and Corporate. The Molecular Diagnostics segment develops molecular diagnostic systems for rapid medical testing and bio-threat detection.